earnings
confidence high
sentiment positive
materiality 0.65
UTMD Q3 2021 EPS $1.150, revenue up 20%; 9M non-GAAP EPS $3.021, up 46%
UTAH MEDICAL PRODUCTS INC
2021-Q3 EPS reported
$2.91
revenue$36,140,000
- Q3 2021 net income $4.2M (33.5% of sales), up 43.4% YoY; diluted EPS $1.150.
- 9M 2021 US GAAP net income $10.7M, up 44.3%; non-GAAP net income $11.0M, up 45.1%.
- Cash and investments at Sep 30, 2021: $64.3M, up from $51.6M at Dec 31, 2020.
- Management expects FY2021 adjusted EBITDA >$26M ($28M for 2022).
- Dividend increased to $0.285/share; total 9M dividends $3.1M.